HIV Vaccine: Vir Biotechnology Announces First Patient Dosed With Novel HIV T-Cell Vaccine in Phase 1 Trial

Vir Biotechnology, Inc., a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced that the first patient was dosed in late December 2020 in a Phase 1 clinical trial of VIR-1111, an investigational human immunodeficiency virus (HIV) T cell vaccine. VIR-1111 is a proof-of-concept vaccine designed to test the hypothesis that this [...]

The post HIV Vaccine: Vir Biotechnology Announces First Patient Dosed With Novel HIV T-Cell Vaccine in Phase 1 Trial appeared first on Outbreak News Today.